Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
191,564,221
-
Total 13F shares
-
172,596,886
-
Share change
-
-2,681,829
-
Total reported value
-
$4,393,814,683
-
Put/Call ratio
-
23%
-
Price per share
-
$25.46
-
Number of holders
-
251
-
Value change
-
-$68,086,150
-
Number of buys
-
140
-
Number of sells
-
107
Institutional Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) as of Q3 2024
As of 30 Sep 2024,
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) was held by
251 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
172,596,886 shares.
The largest 10 holders included
Kohlberg Kravis Roberts & Co. L.P., VIKING GLOBAL INVESTORS LP, VANGUARD GROUP INC, BlackRock, Inc., Aisling Capital Management LP, STATE STREET CORP, JANUS HENDERSON GROUP PLC, Laurion Capital Management LP, Frazier Life Sciences Management, L.P., and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
251
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.